Several studies have indicated decreased tumor sizes, reduced CD4+/CD8+ T cell apoptosis, enhanced T cell proliferation and CTL activity, and decreased Treg cell numbers upon IDO silencing, which was confirmed in vitro, in vivo as well as in patient studies (116, 118). The gene discussed is IDO1; the disease is neoplasm.